<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426633</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-02</org_study_id>
    <nct_id>NCT01426633</nct_id>
  </id_info>
  <brief_title>Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas</brief_title>
  <official_title>Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      L-sarcomas represent about one third of all adult soft tissue sarcomas (24 % liposarcomas and&#xD;
      12 % leiomyosarcomas). Approval for the induction of trabectedin into the treatment&#xD;
      armamentarium of advanced and/or metastatic soft tissue sarcomas after treatment failure with&#xD;
      anthracyclines and/or ifosfamide depended mainly on its activity in the L-sarcomas&#xD;
      (Garcia-Carbonero 2004, Le Cesne 2005, and Demetri 2009). Significant activity has been&#xD;
      described for the use of gemcitabine and especially the combination of gemcitabine and&#xD;
      docetaxel mainly in leiomyosarcomas and liposarcomas (Maki 2007). However, the combination of&#xD;
      gemcitabine and docetaxel is associated with significant toxicity. Pulmonary toxicity and&#xD;
      refractory peripheral oedema are the most common severe adverse events. The aim of the&#xD;
      present phase I study will be to examine safety data of this promising treatment combination&#xD;
      of gemcitabine and trabectedin in L-sarcomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the maximum tolerated dose (MTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the recommended phase II dose (RPTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Leiomyosarcoma</condition>
  <condition>Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Trabectedin</intervention_name>
    <description>Combination therapy of gemcitabine and trabectedin</description>
    <arm_group_label>Gemcitabine + Trabectedin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed L-sarcomas (leiomyosarcoma and liposarcoma)&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  Any treatment line except adjuvant setting: evidence of primary metastatic situation&#xD;
             or disease progression within the last 6 months (based on RECIST 1.1) in computed&#xD;
             tomography or magnetic resonance imaging&#xD;
&#xD;
          -  Any prior treatment possible&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  WHO PS =&lt; 1&#xD;
&#xD;
          -  Effective contraception during study medication and up to 3 months from treatment&#xD;
             discontinuation&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Surgical intervention &lt; 4 weeks&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known allergic reaction to trabectedin or gemcitabine or one of their components&#xD;
&#xD;
          -  The following laboratory values:&#xD;
&#xD;
        Absolute neutrophil count &lt; 1.5 x 103/mm3 Platelets &lt; 100.000/mm3 Hb &lt; 9 g/dL Serum&#xD;
        creatinine &gt;= 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK &gt; 2.5 x ULN&#xD;
        Total bilirubin &gt; 1 x ULN except in the case of Gilbert's syndrome&#xD;
&#xD;
          -  Participation in another study (four weeks before and during the study)&#xD;
&#xD;
          -  Prior malignancy apart from completely resected basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the uterine cervix&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Kasper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Mannheim University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mannheim University Medical Center</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Bernd Kasper</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>L-sarcomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

